Stereotactic ablative radiotherapy versus conventionally fractionated radiotherapy in the treatment of hepatocellular carcinoma with portal vein invasion: a retrospective analysis

Table 3 Univariable and multivariable analysis of the entire cohort

	Univariable		Multivariable (model 1) †		Multivariable (model 2) †
Variable	HR (95% CI)	p	HR (95% CI)	p	HR (95% CI)	p
SABR vs. CFRT	0.615 (0.410–0.924)	0.019	0.623 (0.427–0.909)	0.014
BED < 65 vs. ≥ 65	1.482 (1.039–2.115)	0.030			1.682 (1.150–2.462)	0.007
Time of treatment Before December 31, 2011 vs. after December 31, 2011	1.008 (0.706–1.439)	0.965
Age ≤ 60 vs. > 60	0.882 (0.586–1.327)	0.547
Sex male vs. female	1.094 (0.687–1.741)	0.706
ECOG 0–1 vs. 2	0.554 (0.315–0.977)	0.041	0.523 (0.312–0.877)	0.014	0.572 (0.342–0.957)	0.033
Extrahepatic metastasis yes vs. no	1.731 (0.860–3.484)	0.124
AFP ≤200 vs. > 200	0.606 (0.424–0.866)	0.006	0.566 (0.378–0.846)	0.006	0.520 (0.344–0.785)	0.002
Child-Pugh class A vs. B	0.383 (0.249–0.588)	< 0.001	0.560 (0.381–0.823)	0.003	0.511 (0.345–0.756)	0.001
Prior Treatment yes vs no	0.690 (0.483–0.986)	0.042	0.955 (0.647–1.410)	0.816	0.903 (0.607–1.343)	0.615
Single vs. multiple	0.379 (0.233–0.617)	< 0.001	0.494 (0.323–0.756)	0.001	0.474 (0.308–0.729)	0.001
Tumor size ≤8 vs. > 8	0.452 (0.296–0.689)	< 0.001	0.538 (0.360–0.804)	0.002	0.550 (0.367–0.825)	0.004
Vp3 vs. Vp4	0.641 (0.426–0.964)	0.033	0.678 (0.467–0.985)	0.041	0.685 (0.471–0.995)	0.047
Sorafenib yes vs. no	0.980 (0.685–1.401)	0.911

Abbreviations: SABR Stereotactic ablative radiotherapy, BED Biologically effective dose, ECOG Eastern Cooperative Oncology Group, EM Extrahepatic metastasis, AFP Alpha feto protein, HR Hazard ratio, CI Confidence interval
†BED correlated highly with radiotherapy technique. Two Cox models were used to avoid collinearity

ISSN: 1748-717X